EX-10.1





 Exhibit 10.1 

$475,000,000 
 LIVONGO
HEALTH, INC. 
 0.875% CONVERTIBLE SENIOR NOTES DUE 2025 

PURCHASE AGREEMENT 
  

June 1, 2020 












 June 1, 2020 

Morgan Stanley & Co. LLC 
 Goldman Sachs & Co.
LLC 
 J.P. Morgan Securities LLC 
  

	c/o	 Morgan Stanley & Co. LLC 



1585 Broadway 
 New York, New York
10036 
  

	c/o	 Goldman Sachs & Co. LLC 



200 West Street 
 New York, New
York 10282 
  

	c/o	 J.P. Morgan Securities LLC 



383 Madison Avenue New York, 
 New
York 10179 
 Ladies and Gentlemen: 
 Livongo
Health, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several purchasers named in Schedule I hereto (the “Initial Purchasers”), for whom Morgan Stanley & Co.
LLC, Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as representatives (the “Representatives” or “you”), $475,000,000 principal amount of its 0.875% Convertible Senior Notes due 2025 (the
“Firm Securities”) to be issued pursuant to the provisions of an Indenture dated as of June 4, 2020 (the “Indenture”) between the Company and U.S. Bank National Association, as Trustee (the
“Trustee”). The Company also proposes to issue and sell to the Initial Purchasers not more than an additional $75,000,000 principal amount of its 0.875% Convertible Senior Notes due 2025 (the “Additional
Securities”) if and to the extent that you, as Representatives, shall have determined to exercise, on behalf of the Initial Purchasers, the right to purchase such 0.875% Convertible Senior Notes due 2025 granted to the Initial Purchasers in
Section 2 hereof. The Firm Securities and the Additional Securities are hereinafter collectively referred to as the “Securities”. The Securities will be convertible into cash, shares (the “Underlying
Securities”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) or a combination of cash and Underlying Securities, at the Company’s election. 

In connection with the offering of the Firm Securities, the Company is separately entering into capped call transactions with certain
financial institutions, including with one or more of the Initial Purchasers (or affiliates thereof) (the “Capped Call Counterparties”), in each case pursuant to capped call confirmations (the “Base Capped Call
Confirmations”) to be dated the date hereof, and in connection with any exercise by the Initial Purchasers of their option to purchase any Additional Securities, the Company and the Capped Call Counterparties may enter into additional
capped call transactions 












 
pursuant to additional capped call confirmations (the “Additional Capped Call Confirmations”), each to be dated the date on which the Initial Purchasers exercise their option to
purchase such Additional Securities. The Base Capped Call Confirmations and the Additional Capped Call Confirmations are collectively referred to herein as the “Capped Call Confirmations”. 

The Securities and the Underlying Securities will be offered without being registered under the Securities Act of 1933, as amended (the
“Securities Act”), to qualified institutional buyers in compliance with the exemption from registration provided by Rule 144A under the Securities Act. 

In connection with the sale of the Securities, the Company has prepared a preliminary offering memorandum (the “Preliminary
Memorandum”) and will prepare a final offering memorandum (the “Final Memorandum”) including or incorporating by reference a description of the terms of the Securities and the Underlying Securities, the terms of the
offering and a description of the Company. For purposes of this Agreement, “Additional Written Offering Communication” means any written communication (as defined in Rule 405 under the Securities Act) that constitutes an offer to
sell or a solicitation of an offer to buy the Securities other than the Preliminary Memorandum or the Final Memorandum; “Time of Sale Memorandum” means the Preliminary Memorandum together with each Additional Written Offering
Communication or other information, if any, each identified in Schedule II hereto under the caption Time of Sale Memorandum; and “General Solicitation” means any offer to sell or solicitation of an offer to buy the Securities
by any form of general solicitation or advertising (as those terms are used in Regulation D under the Securities Act). As used herein, the terms Preliminary Memorandum, Time of Sale Memorandum and Final Memorandum shall include the documents, if
any, incorporated by reference therein on the date hereof. The terms “supplement”, “amendment” and “amend” as used herein with respect to the Preliminary Memorandum, the Time of Sale Memorandum, the
Final Memorandum or any Additional Written Offering Communication shall include all documents subsequently filed by the Company with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), that are deemed to be incorporated by reference therein. 
 1. Representations
and Warranties. The Company represents and warrants to, and agrees with, the Representatives that: 
 (a) Each
document, if any, filed or to be filed pursuant to the Exchange Act and incorporated by reference in the Preliminary Memorandum, the Time of Sale Memorandum or the Final Memorandum complied or will comply when so filed in all material respects with
the Exchange Act and the applicable rules and regulations of the Commission thereunder, the Time of Sale Memorandum does not, and at the time of each sale of the Securities in connection with the offering when the Final Memorandum is not yet
available to prospective purchasers and at the Closing Date (as defined in Section 4), the Time of Sale Memorandum, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of a material fact or omit
to 

  
 2 













 
state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, any Additional Written Offering Communication
prepared, used or referred to by the Company, when considered together with the Time of Sale Memorandum, at the time of its use did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading, any General Solicitation that is not an Additional Written Offering Communication, made by the Company or by the Initial Purchaser with the consent of the
Company, when considered together with the Time of Sale Memorandum, at the time when made or used did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading and the Preliminary Memorandum does not contain and the Final Memorandum, in the form used by the Initial Purchasers to confirm sales and on the Closing Date (as defined in Section 4),
will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and
warranties set forth in this paragraph do not apply to statements or omissions in the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum, Additional Written Offering Communication or General Solicitation based upon information
relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the Representatives expressly for use therein. 

(b) Except for the Additional Written Offering Communications, if any, identified in Schedule II hereto, including
electronic road shows, if any, furnished to the Representatives before first use, the Company has not prepared, used or referred to, and will not, without the Representatives’ prior consent, prepare, use or refer to, any Additional Written
Offering Communication. 
 (c) The Company has been duly incorporated, is validly existing as a corporation in good standing
under the laws of the State of Delaware, has the corporate power and authority to own or lease its property and to conduct its business as described in each of the Time of Sale Memorandum and the Final Memorandum and is duly qualified to transact
business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not
reasonably be expected to, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole (a “Material Adverse Effect”). 

(d) Each significant subsidiary (as such term is defined in Rule 1-02 of Regulation S-X under the Exchange Act) of the Company has been duly incorporated, is validly existing as a corporation or in good standing under the laws of the jurisdiction of its incorporation (to the extent the concept of
good standing is applicable in such jurisdiction), has the corporate power and authority 

  
 3 













 
to own its property and to conduct its business as described in each of the Time of Sale Memorandum and the Final Memorandum and is duly qualified to transact business and is in good standing in
each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to have a
Material Adverse Effect; all of the issued shares of capital stock of each significant subsidiary (as such term is defined in Rule 1-02 of Regulation S-X under the
Exchange Act) of the Company have been duly and validly authorized and issued, are fully paid and non-assessable and are owned directly or indirectly by the Company, free and clear of all liens, encumbrances,
equities or claims, except to the extent that such liens, encumbrances, equity or claims would not reasonably be expected to have a Material Adverse Effect. 

(e) This Agreement has been duly authorized, executed and delivered by the Company. 

(f) The authorized capital stock of the Company conforms as to legal matters in all material respects to the description
thereof contained in each of the Time of Sale Memorandum and the Final Memorandum. 
 (g) The shares of Common Stock
outstanding prior to the issuance of the Securities have been duly authorized and are validly issued, fully paid and non-assessable. 

(h) With respect to the stock options granted pursuant to the stock-based compensation plans of the Company and its
subsidiaries (the “Company Stock Plans”), except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, (i) each grant of a stock option was duly authorized no later than the
date on which the grant of such stock option was by its terms to be effective by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and
any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, and (ii) each such grant was made in accordance
with the terms of the Company Stock Plans, and all applicable laws and regulatory rules or requirements, including all applicable federal securities laws. 

(i) The Securities have been duly authorized and, when executed and authenticated in accordance with the provisions of the
Indenture and delivered to and paid for by the Initial Purchasers in accordance with the terms of this Agreement, will be valid and binding obligations of the Company, enforceable in accordance with their terms, subject to the effects of
(i) bankruptcy, insolvency, fraudulent conveyance, fraudulent transfer, reorganization, moratorium or other similar laws relating to or affecting the rights or remedies of creditors generally, (ii) the application of general principles of
equity (including, without limitation, 

  
 4 













 
concepts of materiality, reasonableness, good faith and fair dealing, regardless of whether enforcement is considered in proceedings at law or in equity), and (iii) applicable law and public
policy with respect to rights to indemnity and contribution) (together, the “Enforceability Exceptions”), and will be entitled to the benefits of the Indenture pursuant to which such Securities are to be issued. 

(j) A number of shares of Common Stock equal to the maximum number of shares of Underlying Securities (including the maximum
number of additional shares of Underlying Securities by which the Conversion Rate (as such term is defined in the Indenture) may be increased upon conversion in connection with a Make-Whole Fundamental Change (as such term is defined in the
Indenture) and assuming (x) the Company elects, upon each conversion of the Securities, to deliver solely shares of Common Stock, other than cash in lieu of any fractional shares, in settlement of each such conversion and (y) the
Representatives exercise their option to purchase the Additional Securities in full (the “Maximum Number of Underlying Securities”)) have been duly authorized and reserved and, when issued upon conversion of the Securities in
accordance with the terms of the Securities, will be validly issued, fully paid and non-assessable, and the issuance of the Underlying Securities will not be subject to any preemptive or similar rights. 

(k) The Indenture has been duly authorized and, when executed and delivered by the Company, and, assuming due execution and
delivery thereof by the Trustee, the Indenture will constitute a valid and binding agreement of, the Company, enforceable in accordance with its terms, subject to the effects of the Enforceability Exceptions. 

(l) The Base Capped Call Confirmations have been, and any Additional Capped Call Confirmations on the date or dates that the
Initial Purchasers exercise their right to purchase the relevant Additional Securities will have been, duly authorized, executed and delivered by the Company and, assuming due execution and delivery thereof by the Capped Call Counterparties,
constitute, or will constitute, as the case may be, valid and legally binding agreements of the Company enforceable against the Company in accordance with their terms, subject, as to enforcement, to the effects of the Enforceability Exceptions. 

(m) The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement,
the Indenture, the Securities (including the issuance of the Underlying Securities upon conversion thereof) and the Capped Call Confirmations (together, the “Transaction Documents”) will not contravene any provision of
(i) applicable law, (ii) the certificate of incorporation or by-laws of the Company, (iii) any agreement or other instrument binding upon the Company or any of its subsidiaries that is material
to the Company and its subsidiaries, taken as a whole, or (iv) any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any subsidiary, except that in the case of


  
 5 













 
clauses (i), (iii) and (iv) above, where such contravention would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, or on the power or ability
of the Company to perform its obligations under this Agreement; and no consent, approval, authorization or order of, or qualification with, any governmental body or agency is required for the performance by the Company of its obligations under the
Transaction Documents, except such as has been previously obtained and may be required by the securities or Blue Sky laws of the various states in connection with the offer and sale of the Securities. 

(n) There has not occurred any material adverse change, or any development involving a prospective material adverse change, in
the condition, financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Memorandum. 

(o) Neither the Company nor any of its subsidiaries is (i) in violation of its respective certificate of incorporation or
bylaws; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed
of trust, loan agreement or other agreement or instrument (including any agreement with respect to Company Intellectual Property) to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound
or to which any of the property or assets of the Company or any of its subsidiaries is subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory
authority applicable to the Company, any of its subsidiaries or their respective businesses and properties, except, in the case of clauses (ii) and (iii) above, for any such default or violation that would not, individually or in the aggregate,
have a Material Adverse Effect. 
 (p) There are no legal or governmental proceedings pending or, to the Company’s
knowledge, threatened to which the Company or any of its subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject, other than proceedings accurately described in all material respects in each of
the Time of Sale Memorandum and the Final Memorandum and proceedings that would not reasonably be expected to have a Material Adverse Effect, or on the power or ability of the Company to perform its obligations under the Transaction Documents or to
consummate the transactions contemplated by each of the Time of Sale Memorandum or the Final Memorandum. 
 (q) The Company
and its subsidiaries, taken as a whole, are in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or
wastes, pollutants or contaminants (“Environmental Laws”), have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective


  
 6 













 
businesses and are in compliance with all terms and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required
permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

(r) There are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or
operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential
liabilities to third parties) which would, singly or in the aggregate, have a Material Adverse Effect. 
 (s) The Company is
not, and after giving effect to the offering and sale of the Securities and the application of the proceeds thereof as described in each of the Time of Sale Memorandum and the Final Memorandum, including the transactions contemplated by the Capped
Call Confirmations, will not be, required to register as an “investment company” as such term is defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”). 

(t) Neither the Company nor any affiliate (as defined in Rule 501(b) of Regulation D under the Securities Act, an
“Affiliate”) of the Company has directly, or through any agent, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act) which is or will be integrated
with the sale of the Securities in a manner that would require the registration under the Securities Act of the Securities, made any General Solicitation that is not an Additional Written Offering Communication other than General Solicitations
listed on Schedule II hereto or those made with the prior written consent of the Representatives, or offered, solicited offers to buy or sold the Securities in any manner involving a public offering within the meaning of Section 4(a)(2) of the
Securities Act. 
 (u) Assuming compliance by the Initial Purchasers with respect to their representations in Section 7
of this Agreement, it is not necessary in connection with the offer, sale and delivery of the Securities to the Initial Purchasers in the manner contemplated by this Agreement to register the Securities under the Securities Act or to qualify the
Indenture under the Trust Indenture Act of 1939, as amended. 
 (v) The Securities satisfy the requirements set forth in
Rule 144A(d)(3) under the Securities Act. 
 (w) (i) None of the Company or its subsidiaries or controlled affiliates,
or any director, officer, or employee thereof, or, to the Company’s knowledge, any agent or representative of the Company or of any of its subsidiaries or controlled affiliates, has taken or will take any action in furtherance of an offer,


  
 7 













 
payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property, gifts or anything else of value, directly or indirectly, to any government official
(including any officer or employee of a government or government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or
party official or candidate for political office) in order to improperly influence official action, or to any person in violation of any applicable anti-corruption laws; (ii) the Company and its subsidiaries and controlled affiliates have
conducted their businesses in compliance with applicable anti-corruption laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such laws and with the
representations and warranties contained herein; and (iii) neither the Company nor any of its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of
the payment or giving of money, or anything else of value, to any person in violation of any applicable anti-corruption laws. 

(x) The operations of the Company and its subsidiaries are and have been conducted at all times in material compliance with all
applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act
of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and each of its subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules or regulations
issued, administered or enforced by any governmental or regulatory agency (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental or regulatory agency, authority or
body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened. 

(y) (i) None of the Company, any of its subsidiaries, or any director, officer, or employee thereof, or, to the Company’s
knowledge, any agent, controlled affiliate or representative of the Company or any of its subsidiaries, is an individual or entity (“Person”) that is, or is owned or controlled by one or more Persons that are: 

(A) the subject of any sanctions administered or enforced by the U.S. Department of Treasury’s Office of Foreign Assets
Control, the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”), or 

  
 8 













 (B) located, organized or resident in a country or territory that is the
subject of Sanctions (including, without limitation, Crimea, Cuba, Iran, North Korea and Syria). 
 (ii) If applicable, the Company will
not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person: 

(A) to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of
such funding or facilitation, is the subject of Sanctions; or 
 (B) in any other manner that will result in a violation of
Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise). 

(iii) For the past five years, the Company and its subsidiaries have not knowingly engaged in, are not now knowingly engaged in, and will not
engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions. 

(z) PricewaterhouseCoopers LLP, which expressed its opinion with respect to certain of the financial statements of the Company
and its subsidiaries (which term as used in this Agreement includes the related notes thereto) and supporting schedules included in each of the Time of Sale Memorandum and the Final Memorandum, is an independent registered public accounting firm
with respect to the Company and its subsidiaries within the meaning of the Securities Act and the applicable rules and regulations thereunder adopted by the Commission and the Public Company Accounting Oversight Board (United States). 

(aa) The financial statements, together with the related schedules and notes, included in each of the Time of Sale Memorandum
and the Final Memorandum present fairly the consolidated financial position of the Company and its subsidiaries as of the dates shown and its results of operations and cash flows for the periods shown, and such financial statements have been
prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) applied on a consistent basis throughout the periods covered thereby, except for any normal
year-end adjustments in the Company’s quarterly financial statements. The other financial information included in each of the Time of Sale Memorandum and the Final Memorandum has been derived from the
accounting records of the Company and its consolidated subsidiaries and presents fairly in all material respects the information shown thereby. 

(bb) Subsequent to the respective dates as of which information is given in each of the Time of Sale Memorandum and the Final
Memorandum, the Company and its subsidiaries have not incurred any material liability or 

  
 9 













 
obligation, direct or contingent, nor entered into any material transaction; the Company has not purchased any of its outstanding capital stock (except for acquisitions of capital stock by the
Company pursuant to agreements that permit the Company to repurchase such shares upon the applicable party’s termination of service to the Company or in connection with the exercise of the Company’s right of first refusal upon a proposed
transfer), nor declared, paid or otherwise made any dividend or distribution of any kind on its capital stock other than ordinary and customary dividends; and there has not been any material change in the capital stock (other than the exercise or
forfeiture of equity awards outstanding on such respective dates as of which information is given in each of the Time of Sale Memorandum and the Final Memorandum, in each case granted pursuant to equity compensation plans described in the Time of
Sale Memorandum and the Final Memorandum), short-term debt or long-term debt of the Company and its subsidiaries, taken as a whole, except in each case as described in
each of the Time of Sale Memorandum and the Final Memorandum, respectively. 
 (cc) The Company and its subsidiaries do not
own any real property. The Company and its subsidiaries have good and marketable title to all personal property (other than intellectual property, which is covered by Section 1(ee) below) owned by them which is material to the business of the
Company and its subsidiaries, taken as a whole, in each case free and clear of all liens, encumbrances and defects except such as are described in the Time of Sale Memorandum and the Final Memorandum or such as do not materially diminish the value
of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries; and any real property and buildings held under lease by the Company and its subsidiaries are held by
them under valid, subsisting and, to the Company’s knowledge, enforceable leases with such exceptions as are not material and do not materially interfere with the use made and proposed to be made of such property and buildings by the Company
and its subsidiaries, taken as a whole, in each case except as described in the Time of Sale Memorandum and the Final Memorandum. 

(dd) To their knowledge, the Company and its subsidiaries license, own or otherwise possess, or can acquire on reasonable
terms, all rights in material patents, patent applications, patent rights, licenses, inventions, copyrights, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, inventions, systems or
procedures), trademarks, service marks, trade names and other intellectual property rights, as well as applicable related rights, including moral rights, all goodwill associated with the use of the foregoing, and registrations and applications for
registrations of any of the foregoing, currently employed by them in connection with the business as now conducted and as proposed to be conducted in the Time of Sale Memorandum and the Final Memorandum (the “Company Intellectual
Property”), except where the failure to so license, own or otherwise possess or acquire would not reasonably be expected to have a Material Adverse Effect, and, except as described in the Time of Sale Memorandum and the Final


  
 11 













 
Memorandum, (i) to the Company’s knowledge, there are no third parties who have or will be able to establish ownership or exclusive rights to any Company Intellectual Property, except
for the retained rights of the owners of the Company Intellectual Property which is licensed to the Company; (ii) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others
(a) challenging the validity, enforceability or scope of any Company Intellectual Property or (b) challenging the Company’s rights or any of its subsidiaries’ rights in or to any Company Intellectual Property, and neither the
Company nor any of its subsidiaries is aware of any facts which could form a reasonable basis for any such actions, suits, proceedings or claims; (iii) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding
or claim by others that the Company or any of its subsidiaries infringes or misappropriates, or would upon the commercialization of any product or service in connection with the business as proposed to be conducted, any intellectual property or
other proprietary rights of others and neither the Company nor any of its subsidiaries is aware of any facts which could form a reasonable basis for any such action, suit, proceeding or claim; (iv) to the Company’s knowledge, none of the
Company Intellectual Property used by the Company or its subsidiaries which is necessary to the conduct of its business as now conducted and as proposed to be conducted in the Time of Sale Memorandum and the Final Memorandum by the Company or any of
its subsidiaries has been obtained or is being used by the Company and its subsidiaries in violation of any contractual obligation binding on the Company or its subsidiaries; (v) to the Company’s knowledge, there is no infringement or
misappropriation by others of any Company Intellectual Property owned by the Company or any of its subsidiaries; (vi) to the Company’s knowledge, the Company and its subsidiaries have complied with the terms of each agreement pursuant to
which Company Intellectual Property has been licensed to the Company or any subsidiary, and all such agreements are in full force and effect; (vii) to the Company’s knowledge, there are no material defects in any of the patents or patent
applications included in the Company Intellectual Property; (viii) the Company has taken reasonable steps to protect, maintain and safeguard the Company Intellectual Property, including the execution of appropriate nondisclosure,
confidentiality, and invention assignment agreements; (ix) to the Company’s knowledge, no employee of the Company and its subsidiaries is in or has been in violation of any term of any written employment contract, patent disclosure
agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement, or restrictive covenant agreement with a
former employer where the basis of such violation relates to (a) such employee’s employment with the Company and (b) the ownership by the Company or its subsidiaries of any Company Intellectual Property; (x) none of the Company
Intellectual Property or technology (including information technology and outsourced arrangements) employed by the Company or its subsidiaries has been obtained or is being used by the Company or its subsidiary in violation of any contractual
obligation binding on the Company or its subsidiaries or any of their respective officers, directors or employees or otherwise in violation of the rights of any persons; (xi) the product candidates


  
 11 













 
described in the Time of Sale Memorandum and the Final Memorandum as under development by the Company fall within the scope of the claims of one or more patents or patent applications owned by,
or exclusively licensed to, the Company; and (xii) the duties of candor and good faith required by the United States Patent and Trademark Office during the prosecution of the United States patents and patent applications included in the Company
Intellectual Property have been complied with, except in each case covered by clauses (ii) – (vi) and (ix) – (x) such as would not, if determined adversely to the Company or any of its subsidiaries, have a Material Adverse Effect. 

(ee) Except as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect,
(A) each Plan (as defined below) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to the Employee Retirement Income Security Act of 1974,
as amended (“ERISA”) and the Internal Revenue Code of 1986, as amended (the “Code”); (B) no non-exempt prohibited transaction, within the meaning of Section 406
of ERISA or Section 4975 of the Code, has occurred with respect to any Plan; (C) for each Plan, no failure to satisfy the minimum funding standards (within the meaning of Section 412 of the Code or Section 302
of ERISA), whether or not waived, has occurred or is reasonably expected to occur; (D) no “reportable event” (within the meaning of Section 4043(c) of ERISA, other than those events as to which notice is waived) has occurred
or is reasonably expected to occur; and (E) neither the Company nor any member of its “Controlled Group” (defined as any organization which is a member of a controlled group of corporations within the meaning of Section 414 of
the Code) has incurred, nor is reasonably expected to incur, any liability under Title IV of ERISA (other than contributions to any Plan or any Multiemployer Plan or premiums to the PBGC, in the ordinary course and without default) in
respect of a Plan or a Multiemployer Plan. For purposes of this paragraph, (x) the term “Plan” means an employee benefit plan, within the meaning of Section 3(3) of ERISA, subject to Title IV of ERISA, but excluding any
Multiemployer Plan, for which the Company or any member of its “Controlled Group” has any liability and (y) the term “Multiemployer Plan” means a multiemployer plan within the meaning of Section 4001(a)(3)
of ERISA. 
 (ff) No material labor dispute with the employees of the Company or any of its subsidiaries exists, except
as described in the Time of Sale Memorandum and the Final Memorandum, or, to the knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal
suppliers, manufacturers or contractors that could have a Material Adverse Effect. 
 (gg) The Company and each of its
subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as the Company reasonably believes are prudent and customary in the businesses in which they are engaged; neither the
Company nor any of its subsidiaries has been refused any insurance coverage sought or applied for; and 

  
 12 













 
neither the Company nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar
coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect, except as described in the Time of Sale Memorandum and the Final Memorandum. 

(hh) The Company and its subsidiaries, taken as a whole, possess all certificates, authorizations and permits issued by the
appropriate federal, state or foreign regulatory authorities necessary to conduct their respective businesses, except where the failure to obtain such certificates, authorizations or permits would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect; and neither the Company nor any of its subsidiaries has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, singly or in
the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a Material Adverse Effect, except as described in the Time of Sale Memorandum and the Final Memorandum. 

(ii) The Company and its subsidiaries, taken as a whole, have filed all federal, state, local and foreign tax returns required
to be filed through the date of this Agreement or have requested extensions thereof and have paid all taxes required to be paid thereon (except for cases in which the failure to file or pay would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect, or, except as are currently being contested in good faith and for which reserves required by U.S. GAAP have been created in the financial statements of the Company, or, except to the extent that such taxes
have been accrued on the Company’s financial statements in accordance with U.S. GAAP), and no unpaid tax deficiency has been determined adversely to the Company or any of its subsidiaries which has had (nor does the Company nor any of its
subsidiaries have any notice or knowledge of any unpaid tax deficiency which would reasonably be expected to be determined adversely to the Company or its subsidiaries and which could reasonably be expected to have) a Material Adverse Effect. 

(jj) The Company and its subsidiaries, taken as a whole, maintain a system of internal accounting controls designed to provide
reasonable assurance that transactions are executed in accordance with management’s general or specific authorizations; transactions are recorded as necessary to permit preparation of financial statements in conformity with U.S. GAAP and to
maintain asset accountability; access to assets is permitted only in accordance with management’s general or specific authorization; the recorded accountability for assets is compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences; and the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Preliminary Memorandum, the Time of Sale Memorandum or the Final Memorandum
is accurate. Since the end of the Company’s most recent 

  
 13 













 
audited fiscal year, there has been (i) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and (ii) no change in the
Company’s internal control over financial reporting that has materially and adversely affected, or is reasonably likely to materially and adversely affect, the Company’s internal control over financial reporting. 

(kk) Nothing has come to the attention of the Company that has caused the Company to believe that the statistical, industry and
market related data included in the Time of Sale Memorandum and the Final Memorandum are not based on or derived from sources that are reliable and accurate in all material respects. To the Company’s knowledge, after reasonable investigation,
it has obtained, to the extent required, the consent of the applicable third party for the use of such data. 
 (ll) The
Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Exchange Act) that comply with the requirements of the Exchange Act applicable to the Company; such
disclosure controls and procedures have been designed to ensure that material information relating to the Company and its subsidiaries is made known to the Company’s principal executive officer and principal financial officer by others within
those entities; and such disclosure controls and procedures are effective. 
 (mm) Except as described in the Time of Sale
Memorandum and the Final Memorandum, the Company has not sold, issued or distributed any shares of Common Stock during the six-month period preceding the date hereof, including any sales pursuant to
Rule 144A under, or Regulation D or S of, the Securities Act, other than shares issued pursuant to employee benefit plans, qualified stock option plans or other employee compensation plans or pursuant to outstanding options, rights or
warrants. 
 (nn) In all material respects, the Company is in compliance with all provisions of the Sarbanes-Oxley Act of
2002, as amended (the “Sarbanes-Oxley Act”), and all rules and regulations promulgated thereunder. 
 (oo)
The Company has not taken, directly or indirectly, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Common Stock. 

(pp) The preclinical tests and clinical trials, and other studies (collectively, “Studies”) that are described
in, or the results of which are referred to in, the Time of Sale Memorandum or the Final Memorandum were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and
approved for such Studies and with standard medical and scientific research procedures; each description of the results of such Studies is accurate and complete in all material respects and fairly presents the data derived from such Studies; the
Company has made all filings and obtained all approvals or authorizations required by the Food and Drug 

  
 14 













 
Administration of the U.S. Department of Health and Human Services or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional
Review Board (collectively, the “Regulatory Agencies”), except where the failure to make such filing or obtain such approval would not reasonably be expected to, individually or in the aggregate, result in a Material Adverse Effect;
and the Company has operated and currently is in compliance in all material respects with all applicable laws, rules and regulations of the Regulatory Agencies. 

(qq) The Company and its subsidiaries are, and at all times have been, except as would not reasonably be expected to have a
Material Adverse Effect, in compliance with all applicable Health Care Laws, as defined below, including all binding rules and regulations thereunder. For purposes of this Agreement, “Health Care Laws” means: (i) the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. §§ 301 et seq.) and the regulations promulgated thereunder; (ii) all applicable federal, state, local and all applicable foreign health care related fraud and abuse laws, including, without
limitation, the U.S. Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)), the U.S. False Statements Law (42 U.S.C. § 1320a-7b(a)), the Civil Monetary Penalties Law
(42 U.S.C. §1320a-7a), the U.S. Civil False Claims Act (31 U.S.C. § 3729 et seq.), all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. §§ 286
and 287, and the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) (42 U.S.C. §§1320d et seq.), the Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h), the exclusions law (42 U.S.C. § 1320a-7), the statutes, regulations and directives of applicable government funded or sponsored healthcare programs, and the
regulations promulgated pursuant to such statutes, including but not limited to the coverage and payment provisions of Medicare (Title XVIII of the Social Security Act) and, Medicaid (Title XIX of the Social Security Act); (iii) the Standards for
Privacy of Individually Identifiable Health Information (the “Privacy Rule”), the Security Standards, and the Standards for Electronic Transactions and Code Sets promulgated under HIPAA, the Health Information Technology for Economic and
Clinical Health Act (“HITECH Act”) (42 U.S.C. §§ 17921 et seq.), and the regulations promulgated thereunder and any state or non-U.S. counterpart thereof or other law or regulation the
purpose of which is to protect the privacy of individuals or prescribers; and (iv) any and all other applicable health care laws and regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use,
distribution, marketing, advertising, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company. Neither the Company nor its subsidiaries has received written notice of
any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in material
violation of any Health Care Laws, and, to the Company’s knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened. Neither the Company, its subsidiaries, nor any of their
officers, directors, 

  
 15 













 
employees, contractors and agents, is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any
governmental or regulatory authority. Additionally, neither the Company including any of its employees, contractors, agents, officers or directors, nor its subsidiaries including any of the subsidiary’s employees, contractors, agents, officers
or directors has been excluded, suspended or debarred from participation in any U.S. federal health care program or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could
reasonably be expected to result in debarment, suspension, or exclusion. The Company and its subsidiaries have filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and
supplements or amendments as required by the Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were timely, complete, accurate and not misleading on the date
filed in all material respects (or were corrected or supplemented by a subsequent submission). 
 (rr) The Company and each
of its subsidiaries are, and at all prior times during the past five (5) years were, except as would not reasonably be expected to have a Material Adverse Effect, in compliance with all applicable data privacy and security laws and regulations
regarding their collection, use, transfer, storage, protection, disposal or disclosure of Personal Data (as defined below) collected from or provided by third parties, including, to the extent applicable, the European Union General Data Protection
Regulation (“GDPR”) (EU 2016/679) (collectively, the “Privacy Laws”) (and, except as would not reasonably be expected to have a Material Adverse Effect, have taken commercially reasonable steps to prepare to comply
as of their respective effective dates with all other applicable data privacy and security laws and regulations with respect to Personal Data that have been announced as of the date hereof as becoming effective within 6 months after the date hereof,
including but not limited to the California Consumer Privacy Act of 2018 (to the extent applicable), and for which any non-compliance with same would be reasonably likely to create a material liability).
“Personal Data” means, to the extent applicable, (i) a natural person’s name, street address, telephone number, e-mail address, photograph, social security number or tax
identification number, driver’s license number, passport number, credit card number, bank information, or customer or account number; (ii) any information which would qualify as “personally identifying information” under the
Federal Trade Commission Act, as amended; and (iii) “personal data” as defined by GDPR. Except as would not have a Material Adverse Effect, (i) the Company and its subsidiaries have in place, comply with, and take appropriate steps
reasonably designed to ensure compliance in all material respects with their (i) policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data, and
(ii) security policies (collectively, the “Policies”); and (ii) each of the Policies provides accurate notice, sufficient for compliance with applicable Privacy Laws, of the Company’s then-current privacy practices.
The execution, delivery and 

  
 16 













 
performance by the Company and its subsidiaries of this Agreement or any other agreement referred to in this Agreement will not result in a material breach or violation by the Company or any of
its subsidiaries of any applicable Privacy Laws. Neither the Company nor any subsidiary: (i) to the Company’s knowledge, except as would not be material to the Company and its subsidiaries, taken as a whole, has received notice of any
actual or potential liability under or relating to, or actual or potential violation of, any applicable Privacy Laws; or (ii) other than agreements requiring compliance with Privacy Laws entered into in the ordinary course of business, is a
party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law. 
 (ss) Except as
would not reasonably be expected to have a Material Adverse Effect, (i) the Company and its subsidiaries’ information technology assets and equipment, computers, technology systems and other systems, networks, hardware, software, websites,
applications, and databases (collectively, “IT Systems”) operate and perform as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, and to the knowledge of the
Company, are free and clear of all material bugs, errors, defects, Trojan horses, time bombs, and other malware; (ii) the Company and its subsidiaries implement and maintain commercially reasonable controls, policies, procedures, and safeguards
designed to maintain and protect their confidential information and the integrity, operation, redundancy and security of all IT Systems and the security of (including all Personal Data and sensitive, confidential or regulated data in their
possession or control that are used in connection with the operation of the Company or its subsidiaries (collectively, the “Confidential Data”)); (iii) the Company and its subsidiaries have in the past five (5) years used
reasonable efforts to establish, and have established, commercially reasonable disaster recovery and security plans, procedures and facilities for the business, including, without limitation, for the IT Systems; (iv) in the past five
(5) years, there have been no security incidents of the IT Systems or unauthorized uses of or accesses to the Confidential Data (except for those that have been remedied without material cost or liability or the duty to notify any other
person); and (v) the Company and its subsidiaries are presently in compliance with all applicable laws or statutes and all applicable judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority,
and all of the Company’s and its subsidiaries’ internal policies and contractual obligations relating to the security of IT Systems and privacy and data security with regard to Confidential Data. 

(tt) The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Preliminary
Memorandum, the Time of Sale Memorandum or the Final Memorandum fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto. 

2. Agreements to Sell and Purchase. The Company hereby agrees to sell to the several Initial Purchasers, and each Initial Purchaser,
upon the basis of the 

  
 17 













 
representations and warranties herein contained, but subject to the terms and conditions hereinafter stated, agrees, severally and not jointly, to purchase from the Company the respective
principal amount of Firm Securities set forth in Schedule I hereto opposite its name at a purchase price of 97.25% of the principal amount thereof (the “Purchase Price”) plus accrued interest, if any, to the Closing Date. 

On the basis of the representations and warranties contained in this Agreement, and subject to its terms and conditions, the Company agrees to
sell to the Initial Purchasers the Additional Securities, and the Initial Purchasers shall have the right to purchase, severally and not jointly, up to $75,000,000 principal amount of Additional Securities at the Purchase Price plus accrued
interest, if any, to the date of payment and delivery. The Representatives may exercise this right on behalf of the Initial Purchasers in whole or from time to time in part by giving written notice to the Company, provided that any Option Closing
Date (as defined below) shall occur within a period (the “Exercise Period”) of thirteen calendar days from, and including, the Closing Date (as defined in Section 4). Any exercise notice shall specify the principal amount of
Additional Securities to be purchased by the Initial Purchasers and the date on which such Additional Securities are to be purchased. Each purchase date must be within the Exercise Period, and must be at least one business day after the written
notice is given and may not be earlier than the Closing Date (as defined in Section 4) nor later than ten business days after the date of such notice. Additional Securities may be purchased as provided in Section 4 solely for the purpose
of covering sales of securities in excess of the number of the Firm Securities. On each day, if any, that Additional Securities are to be purchased (an “Option Closing Date”), each Initial Purchaser agrees, severally and not
jointly, to purchase the principal amount of Additional Securities (subject to such adjustments to eliminate fractional Securities as the Representatives may determine) that bears the same proportion to the total principal amount of Additional
Securities to be purchased on such Option Closing Date as the principal amount of Firm Securities set forth in Schedule I opposite the name of such Initial Purchaser bears to the total principal amount of Firm Securities. 

3. Terms of Offering. The Representatives have advised the Company that the Initial Purchasers will make an offering of the
Securities purchased by the Initial Purchasers hereunder as soon as practicable after this Agreement is entered into as in the Representatives’ judgment is advisable. 

4. Payment and Delivery. Payment for the Firm Securities shall be made to the Company in Federal or other funds immediately available
in New York City against delivery of such Firm Securities for the respective accounts of the several Initial Purchasers at 10:00 a.m., New York City time, on June 4, 2020, or at such other time on the same or such other date, not later than
June 11, 2020, as shall be designated in writing by the Representatives. The time and date of such payment are hereinafter referred to as the “Closing Date.” 

Payment for any Additional Securities shall be made to the Company in Federal or other funds immediately available in New York City against
delivery of such Additional Securities for the respective accounts of the several Initial Purchasers at 

  
 18 













 
10:00 a.m., New York City time, on the date specified in the corresponding notice described in Section 2 or at such other time on the same or on such other date, in any event not later
than the last day of the Exercise Period, as shall be designated in writing by the Representatives. 
 The Securities shall be in definitive
form or global form, as specified by the Representatives, and registered in such names and in such denominations as the Representatives shall request in writing not later than one full business day prior to the Closing Date or the applicable Option
Closing Date, as the case may be. The Securities shall be delivered to the Representatives on the Closing Date or an Option Closing Date, as the case may be, for the respective accounts of the several Initial Purchasers, with any transfer taxes
payable in connection with the transfer of the Securities duly paid by the Company. 
 5. Conditions to the Initial
Purchasers’ Obligations. The several obligations of the Initial Purchasers to purchase and pay for the Firm Securities on the Closing Date are subject to the following conditions: 

(a) Subsequent to the execution and delivery of this Agreement and prior to the Closing Date: 

(i) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential
downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any of the securities of the Company or any of its subsidiaries by any “nationally recognized statistical
rating organization,” as such term is defined in Section 3(a)(62) of the Exchange Act; and 
 (ii) there shall not
have occurred any change, or any development involving a prospective change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time
of Sale Memorandum provided to the prospective purchasers of the Securities that, in the judgment of the Representatives, is material and adverse and that makes it, in the judgment of the Representatives, impracticable to market the Securities on
the terms and in the manner contemplated in the Time of Sale Memorandum. 
 (b) The Initial Purchasers shall have received on
the Closing Date a certificate, dated the Closing Date and signed on behalf of the Company by an executive officer of the Company, to the effect set forth in Sections 5(a)(i) and 5(a)(ii) above and to the effect that the representations and
warranties of the Company contained in this Agreement are true and correct as of the Closing Date and that the Company has complied with all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on
or before the Closing Date. 

  
 19 













 The officer signing and delivering such certificate may rely upon his or her
knowledge as to proceedings threatened. 
 (c) The Initial Purchasers shall have received on the Closing Date an opinion and
negative assurance letter of Wilson Sonsini Goodrich & Rosati, Professional Corporation, outside counsel for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Representatives. 

(d) The Initial Purchasers shall have received on the Closing Date an opinion and negative assurance letter of Cooley LLP,
counsel for the Initial Purchasers, dated the Closing Date, in form and substance satisfactory to the Representatives. 

With respect to Sections (c) and (d) above, Wilson Sonsini Goodrich & Rosati, Professional Corporation and Cooley
LLP may state that their opinions and beliefs are based upon their participation in the preparation of the Time of Sale Memorandum and the Final Memorandum and any amendments or supplements thereto and review and discussion of the contents thereof,
but are without independent check or verification, except as specified. 
 The opinion and negative assurance letter of
Wilson Sonsini Goodrich & Rosati, Professional Corporation described in Section 5(c) above shall be rendered to the Initial Purchasers at the request of the Company and shall so state therein. 

(e) The Initial Purchasers shall have received on each of the date hereof and the Closing Date a letter, dated the date hereof
or the Closing Date, as the case may be, in form and substance satisfactory to the Initial Purchasers, from PricewaterhouseCoopers LLP, an independent registered public accounting firm, containing statements and information of the type ordinarily
included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained in or incorporated by reference into the Time of Sale Memorandum and the Final Memorandum;
provided that the letter delivered on the Closing Date shall use a “cut-off date” not earlier than the date hereof. 

(f) The “lock-up” agreements, each substantially in the form of
Exhibit A hereto, executed by certain securityholders, and all executive officers and directors of the Company relating to restrictions on sales and certain other dispositions of shares of Common Stock or certain other securities, delivered to
the Representatives on or before the date hereof, shall be in full force and effect on the Closing Date. 
 (g) The chief
financial officer of the Company shall have delivered to the Initial Purchasers, on each of the date hereof and on the Closing Date, a certificate in a form reasonably acceptable to the Representatives. 

  
 20 













 (h) The Securities shall be eligible for clearance and settlement through
The Depository Trust Company; 
 (i) An application for the listing of the Underlying Securities shall have been submitted to
the Nasdaq Global Select Market; 
 (j) The several obligations of the Initial Purchasers to purchase Additional Securities
hereunder are subject to the delivery to the Representatives on the applicable Option Closing Date of the following: 
 (i) a
certificate, dated the Option Closing Date and signed by an executive officer of the Company, confirming that the certificate delivered on the Closing Date pursuant to Section 5(b) hereof remains true and correct as of such Option Closing Date;

 (ii) an opinion and negative assurance letter of Wilson Sonsini Goodrich & Rosati, Professional Corporation,
outside counsel for the Company, dated the Option Closing Date, relating to the Additional Securities to be purchased on such Option Closing Date and otherwise to the same effect as the opinion and negative assurance letter required by
Section 5(c) hereof; 
 (iii) an opinion and negative assurance letter of Cooley LLP, counsel for the Initial
Purchasers, dated the Option Closing Date, relating to the Additional Securities to be purchased on such Option Closing Date and otherwise to the same effect as the opinion and negative assurance letter required by Section 5(d) hereof; 

(iv) a letter dated the Option Closing Date, in form and substance satisfactory to the Initial Purchasers, from
PricewaterhouseCoopers LLP, an independent registered public accounting firm, substantially in the same form and substance as the letter furnished to the Initial Purchasers pursuant to Section 5(e) hereof; provided that the letter
delivered on the Option Closing Date shall use a “cut-off date” not earlier than three business days prior to such Option Closing Date; 

(v) a certificate, dated the Option Closing Date and signed by the chief financial officer of the Company substantially in the
same form and substance as the letter furnished to the Initial Purchasers pursuant to Section 5(g) hereof; and 
 (vi)
such other documents as the Representatives may reasonably request with respect to the good standing of the Company, the due authorization of the Additional Securities to be sold on such Option Closing Date and other matters related to the sale of
such Additional Securities. 

  
 21 













 6. Covenants of the Company. The Company covenants with each Initial Purchaser
as follows: 
 (a) To furnish to the Representatives in New York City, without charge, prior to 10:00 a.m. New York City
time on the business day next succeeding the date of this Agreement and during the period mentioned in Section 6(d) or (e), as many copies of the Time of Sale Memorandum, the Final Memorandum, any documents incorporated by reference therein and
any supplements and amendments thereto as the Representatives may reasonably request. 
 (b) Before amending or supplementing
the Preliminary Memorandum, the Time of Sale Memorandum or the Final Memorandum, to furnish to the Representatives a copy of each such proposed amendment or supplement and not to file any such proposed amendment or supplement to which the
Representatives reasonably object. 
 (c) To furnish to the Representatives a copy of each proposed Additional Written
Offering Communication to be prepared by or on behalf of, used by, or referred to by the Company and not to use or refer to any proposed Additional Written Offering Communication to which the Representatives reasonably object. 

(d) If the Time of Sale Memorandum is being used to solicit offers to buy the Securities at a time when the Final Memorandum is
not yet available to prospective purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Memorandum in order to make the statements therein, in the light of the
circumstances, not misleading, or if, in the opinion of counsel for the Initial Purchasers, it is necessary to amend or supplement the Time of Sale Memorandum to comply with applicable law, forthwith to prepare and furnish, at its own expense, to
the Initial Purchasers and to any dealer upon request, either amendments or supplements to the Time of Sale Memorandum so that the statements in the Time of Sale Memorandum as so amended or supplemented will not, in the light of the circumstances
when the Time of Sale Memorandum is delivered to a prospective purchaser, be misleading or so that the Time of Sale Memorandum, as amended or supplemented, will comply with applicable law. 

(e) If, during such period after the date hereof and prior to the date on which all of the Securities shall have been sold by
the Initial Purchasers, any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Final Memorandum in order to make the statements therein, in the light of the circumstances when the Final Memorandum is
delivered to a purchaser, not misleading, or if, in the opinion of counsel for the Initial Purchasers, it is necessary to amend or supplement the Final Memorandum to comply with applicable law, forthwith to prepare and furnish, at its own expense,
to the Initial Purchasers and to the dealers (whose names and addresses the 

  
 22 













 
Representatives will furnish to the Company) to which Securities may have been sold by the Representatives on behalf of the Initial Purchasers and to any other dealers upon request, either
amendments or supplements to the Final Memorandum so that the statements in the Final Memorandum as so amended or supplemented will not, in the light of the circumstances when the Final Memorandum is delivered to a purchaser, be misleading or so
that the Final Memorandum, as amended or supplemented, will comply with applicable law. 
 (f) To endeavor to qualify the
Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request; provided that in no event shall the Company be obligated to qualify to do business in any jurisdiction
where it is not now so qualified or to take any action that would subject it to service of process in suits, other than those arising out of the offering or sale of the Securities, or taxation in any jurisdiction where it is not now so subject. 

(g) To make generally available to the Company’s security holders and to the Representatives as soon as practicable an
earnings statement covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of Section 11(a) of the Securities Act and the
rules and regulations of the Commission thereunder. 
 (h) Whether or not the transactions contemplated in this Agreement are
consummated or this Agreement is terminated, the Company shall pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement, including: the fees, disbursements and expenses of the Company’s counsel
and the Company’s accountants in connection with the issuance and issuance of the Securities and all other fees or expenses in connection with the preparation of the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum, any
Additional Written Offering Communication prepared by or on behalf of, used by, or referred to by the Company and amendments and supplements to any of the foregoing, including all printing costs associated therewith, and the mailing and delivering
of copies thereof to the Initial Purchasers and dealers, in the quantities herein above specified, all costs and expenses related to the transfer and delivery of the Securities to the Initial Purchasers, including any transfer or other taxes payable
thereon, the reasonable cost of printing or producing any Blue Sky or legal investment memorandum in connection with the offer and sale of the Securities under state securities laws and all expenses in connection with the qualification of the
Securities for offer and sale under state securities laws as provided in Section 6(f) hereof, including filing fees and the reasonable and documented fees and disbursements of counsel for the Initial Purchasers in connection with such
qualification and in connection with the Blue Sky or legal investment memorandum (provided that the amount payable by the Company with respect to the fees and disbursements of counsel for the Initial Purchasers incurred pursuant to this subsection
(iii) of Section 6(h) shall not exceed $10,000 in the aggregate), 

  
 23 













 
any fees charged by rating agencies for the rating of the Securities, (i) the fees and expenses, if any, incurred in connection with the admission of the Securities for trading any
appropriate market system, (ii) all costs and expenses incident to listing the Underlying Securities on the Nasdaq Global Market, the costs and charges of the Trustee and any transfer agent, registrar or depositary, the costs and expenses of
the Company relating to investor presentations on any “road show” undertaken in connection with the marketing of the offering of the Securities, including, without limitation, expenses associated with the preparation or dissemination of
any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and
lodging expenses of the representatives and officers of the Company and any such consultants, and fifty percent (50%) of the cost of any aircraft chartered in connection with the road show for use by the Company and the Initial Purchasers (the
remaining fifty percent (50%) of the cost of such aircraft to be paid by the Initial Purchasers), (iii) the document production charges and expenses associated with printing this Agreement and (iv) all other costs and expenses incident to
the performance of the obligations of the Company hereunder for which provision is not otherwise made in this Section. It is understood, however, that except as provided in this Section, Section 8, and the last paragraph of Section 10, the
Initial Purchasers will pay all of their costs and expenses, including fees and disbursements of their counsel, stock transfer taxes payable on resale of any of the Securities by them and any advertising expenses connected with any offers they may
make and any travel and lodging costs incurred by them in connection with any road show. 
 (i) Neither the Company nor any
Affiliate will sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in the Securities Act) which could be integrated with the sale of the Securities in a manner which would require the
registration under the Securities Act of the Securities. 
 (j) To furnish the Representatives with any proposed General
Solicitation to be made by the Company or on its behalf before its use, and not to make or use any proposed General Solicitation without the Representatives’ prior written consent. 

(k) The Company will promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time
prior to the later of (a) completion of the distribution of the Securities within the meaning of the Securities Act and (b) completion of the Restricted Period (as defined in this Section 6). 

(l) While any of the Securities or the Underlying Securities remain “restricted securities” within the meaning of the
Securities Act, to make available, upon request, to any seller of such Securities the information specified in Rule 144A(d)(4) under the Securities Act, unless the Company is then subject to Section 13 or 15(d) of the Exchange Act. 

  
 24 













 (m) During the period of one year after the Closing Date or any Option
Closing Date, if later, the Company will not be, nor will it become, an open-end investment company, unit investment trust or face-amount certificate company that is or is required to be registered under
Section 8 of the Investment Company Act. 
 (n) During the period of one year after the Closing Date or any Option
Closing Date, if later, the Company will not, and will not permit any person that is an affiliate (as defined in Rule 144 under the Securities Act) at such time (or has been an affiliate within the three months preceding such time) to, resell any of
the Securities or the Underlying Securities which constitute “restricted securities” under Rule 144 that have been reacquired by any of them. 

(o) Not to take any action prohibited by Regulation M under the Exchange Act in connection with the distribution of the
Securities contemplated hereby. 
 (p) For as long as the Securities are outstanding, to cause to be listed, and maintain the
listing of, the Underlying Securities on the Nasdaq Global Select Market. 
 (q) To reserve and keep available at all times,
free of preemptive rights, shares of Common Stock in an amount equal to the Maximum Number of Underlying Securities for the purpose of enabling the Company to satisfy all obligations to issue Underlying Securities upon conversion of the Securities.

 The Company also covenants with each Initial Purchaser that, without the prior written consent of the Representatives on behalf of the
Initial Purchasers, it will not, during the period ending 90 days after the date of the Final Memorandum (the “Restricted Period”), and will not publicly disclose an intention to, (1) offer, pledge, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible
into or exercisable or exchangeable for Common Stock or (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction
described in clause (1) or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (3) confidentially submit any draft registration statement or file any registration statement with the
Commission relating to the offering of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock. 

The restrictions contained in the preceding paragraph shall not apply to (a) the sale of the Securities under this Agreement,
(b) the issuance by the Company of shares of 

  
 25 













 
Common Stock upon the exercise of an option or warrant or the conversion of a security outstanding on the date hereof of which the Initial Purchasers have been advised in writing, (c) the
grant of options, restricted stock units or any other type of equity award described in the Time of Sale Memorandum and the Final Memorandum pursuant to employee benefit plans in effect on the date hereof and described in the Time of Sale Memorandum
and the Final Memorandum, or the issuance of shares of Common Stock by the Company (whether upon the exercise of stock options or other equity awards) to employees, officers, directors, advisors or consultants of the Company pursuant to employee
benefit plans in effect on the date hereof and described in the Time of Sale Memorandum and the Final Memorandum; provided that each newly appointed director or executive officer (including a newly appointed director or executive officer that
is appointed during the Restricted Period) that is a recipient of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock pursuant to this clause (c) shall execute a
lock-up agreement substantially in the form of Exhibit A hereto with respect to the remaining portion of the Restricted Period, (d) the filing by the Company of a registration statement on Form S-8 relating to the issuance, vesting, exercise or settlement of equity awards granted or to be granted pursuant to any employee benefit plan in effect on the date hereof and described in the Time of Sale
Memorandum, (e) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Common Stock, provided that (i) such plan does not provide for
the transfer of Common Stock during the Restricted Period and (ii) to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by the Company regarding the establishment of such plan, such
announcement or filing shall include a statement to the effect that no transfer of Common Stock may be made under such plan during the Restricted Period, or (f) the issuance of or entry into an agreement to issue Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock in connection with one or more mergers; acquisitions of securities, businesses, property or other assets, products or technologies; joint ventures; commercial relationships or other
strategic corporate transactions or alliances; provided that the aggregate amounts of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (on an as-converted,
as-exercised or as-exchanged basis) that the Company may issue or agree to issue pursuant to this paragraph shall not exceed 10% of the total number of shares of Common
Stock of the Company issued and outstanding immediately following the completion of the transactions contemplated by this Agreement determined on a fully-diluted basis, and provided further that each newly appointed director or executive
officer (including a newly appointed director or executive officer that is appointed during the Restricted Period) that is a recipient of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock pursuant to
this clause (f) shall execute a lock-up agreement substantially in the form of Exhibit A hereto with respect to the remaining portion of the Restricted Period. 

7. Offering of Securities; Restrictions on Transfer. Each Initial Purchaser, severally and not jointly, represents and warrants that
such Initial Purchaser is a qualified institutional buyer as defined in Rule 144A under the Securities Act (a “QIB”). Each Initial Purchaser, severally and not jointly, agrees with the Company that it will not solicit offers
for, or offer or sell, such Securities by any General Solicitation, other than a 

  
 26 













 
permitted communication listed on Schedule II hereto, or those made with the prior written consent of the Company, or in any manner involving a public offering within the meaning of
Section 4(a)(2) of the Securities Act, it will sell such Securities in the United States only to persons that it reasonably believes to be QIBs, in purchasing such Securities are deemed to have represented and agreed as provided in the Final
Memorandum under the captions “Notice to Investors” and “Transfer Restrictions”. 
 (a) The Company
agrees that the Initial Purchasers may provide copies of the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum and any other agreements or documents relating thereto, including without limitation, the Indenture, to Xtract
Research LLC (“Xtract”), following completion of the offering, for inclusion in an online research service sponsored by Xtract, access to which shall be restricted by Xtract to QIBs. 

8. Indemnity and Contribution. The Company agrees to indemnify and hold harmless each Initial Purchaser, each person, if any, who
controls any Initial Purchaser within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act, and each affiliate of any Initial Purchaser within the meaning of Rule 405 under the Securities Act from
and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) that arise out of, or are based
upon, any untrue statement or alleged untrue statement of a material fact contained in the Preliminary Memorandum, the Time of Sale Memorandum, any Additional Written Offering Communication prepared by or on behalf of, used by, or referred to by the
Company, any General Solicitation made by the Company, any “road show” as defined in Rule 433(h) under the Securities Act (a “road show”), the Final Memorandum or any amendment or supplement thereto, or arise out of, or are based
upon, any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein in the light of the circumstances under which they were made not misleading, except insofar as such
losses, claims, damages or liabilities arise out of, or are based upon, any such untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any Initial Purchaser
furnished to the Company in writing by such Initial Purchaser through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by the Initial Purchaser through the Representatives
consists of the information described as such in paragraph (b) below. The Company agrees and confirms that references to “affiliates” of Morgan Stanley that appear in this Agreement shall be understood to include Mitsubishi UFJ Morgan
Stanley Securities Co., Ltd. 
 (a) Each Initial Purchaser agrees, severally and not jointly, to indemnify and hold harmless
the Company, its directors, its officers and each person, if any, who controls the Company within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the foregoing indemnity from
the Company to such Initial Purchaser, but only with reference to information relating to such Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the Representatives


  
 27 













 
expressly for use in the Preliminary Memorandum, the Time of Sale Memorandum, any Additional Written Offering Communication set forth in Schedule II hereto, road show, General Solicitation set
forth in Schedule II hereto, the Final Memorandum or any amendment or supplement thereto it being understood and agreed that the only information furnished by any such Initial Purchaser consists of the following information in the Final Memorandum
furnished on behalf of each Initial Purchaser: (i) the first sentence of the seventh paragraph of text under the caption “Plan of Distribution” concerning the terms of the offering by the Initial Purchasers, and (ii) the first,
fourth and fifth sentences of the fourteenth paragraph of text under the caption “Plan of Distribution” concerning stabilization. 

(b) In case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of
which indemnity may be sought pursuant to Section 8(a) or 8(b), such person (the “indemnified party”) shall promptly notify the person against whom such indemnity may be sought (the “indemnifying party”) in
writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may designate in such
proceeding and shall pay the reasonably incurred and documented fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and
expenses of such counsel shall be at the expense of such indemnified party unless the indemnifying party and the indemnified party shall have mutually agreed in writing to the retention of such counsel or the named parties to any such proceeding
(including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is
understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one
separate firm (in addition to any local counsel) for all such indemnified parties and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by the Representatives, in the case of parties
indemnified pursuant to Section 8(a), and by the Company, in the case of parties indemnified pursuant to Section 8(b). The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent,
but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the
foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by the second and third sentences of this paragraph, the
indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 60 days after receipt by such indemnifying party of the aforesaid
request and (ii) such indemnifying party shall 

  
 28 













 
not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified
party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement
(x) includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding and (y) does not include a statement as to or an admission of fault, culpability or a failure to
act by or on behalf of any indemnified party. 
 (c) To the extent the indemnification provided for in Section 8(a) or
8(b) is unavailable to an indemnified party or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party thereunder,
shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities in such proportion as is appropriate to reflect the relative benefits received by the indemnifying party or parties
on the one hand and the indemnified party or parties on the other hand from the offering of the Securities or if the allocation provided by clause 8(d)(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect
not only the relative benefits referred to in clause 8(d)(i) above but also the relative fault of the indemnifying party or parties on the one hand and of the indemnified party or parties on the other hand in connection with the statements or
omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the indemnifying party or parties on the one hand and the indemnified party or parties
on the other hand in connection with the offering of the Securities shall be deemed to be in the same respective proportions as the net proceeds from the offering of the Securities (after deducting discounts and commissions but before deducting
expenses) received by the Company and the total discounts and commissions received by the Initial Purchasers, in each case as set forth on the cover of the Final Memorandum, bear to the aggregate offering price of the Securities. The relative fault
of the indemnifying party or parties on the one hand and the indemnified party or parties on the other hand shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or
alleged omission to state a material fact relates to information supplied by the Company or by the Initial Purchasers and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or
omission. The Initial Purchasers’ respective obligations to contribute pursuant to this Section 8 are several in proportion to the respective principal amount of Securities they have purchased hereunder, and not joint. 

(d) The Company and the Initial Purchasers agree that it would not be just or equitable if contribution pursuant to this
Section 8 were determined by pro rata allocation (even if the Initial Purchasers were treated as one entity for such purpose) or by any other method of allocation that does not take account of the


  
 29 













 
equitable considerations referred to in Section 8(d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in
Section 8(d) shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this Section 8, no Initial Purchaser shall be required to contribute any amount in excess of the amount by which the total price at which the Securities resold by it in the initial placement of such Securities
were offered to investors exceeds the amount of any damages that such Initial Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The remedies provided for in this Section 8 are not
exclusive and shall not limit any rights or remedies which may otherwise be available to any indemnified party at law or in equity. 

(e) The indemnity and contribution provisions contained in this Section 8 and the representations, warranties and other
statements of the Company contained in this Agreement shall remain operative and in full force and effect regardless of any termination of this Agreement, any investigation made by or on behalf of any Initial Purchaser, any person controlling any
Initial Purchaser or any affiliate of any Initial Purchaser or by or on behalf of the Company, its officers or directors or any person controlling the Company and acceptance of and payment for any of the Securities. 

9. Termination. The Initial Purchasers may terminate this Agreement by notice given by the Representatives to the Company, if
after the execution and delivery of this Agreement and prior to or on the Closing Date, or any Option Closing Date, as the case may be, trading generally shall have been suspended or materially limited on, or by, as the case may be, any of the New
York Stock Exchange, the Nasdaq Global Market, the Chicago Board of Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of Trade or other relevant exchanges, trading of any securities of the Company shall have been suspended on
any exchange or in any over-the-counter market, a material disruption in securities settlement, payment or clearance services in the United States shall have occurred,
any moratorium on commercial banking activities shall have been declared by Federal or New York State authorities or there shall have occurred any outbreak or escalation of hostilities, or any change in financial markets or any calamity or crisis
that, in the judgment of the Representatives, is material and adverse and which, singly or together with any other event specified in this clause (v), makes it, in the judgment of the Representatives, impracticable or inadvisable to proceed with the
offer, sale or delivery of the Securities on the terms and in the manner contemplated in the Time of Sale Memorandum or the Final Memorandum. 

10. Effectiveness; Defaulting Initial Purchasers. This Agreement shall become effective upon the execution and delivery hereof by the
parties hereto. 

  
 30 













 If, on the Closing Date, or an Option Closing Date, as the case may be, any one or more of
the Initial Purchasers shall fail or refuse to purchase Securities that it or they have agreed to purchase hereunder on such date, and the aggregate principal amount of Securities which such defaulting Initial Purchaser or Initial Purchasers agreed
but failed or refused to purchase is not more than one-tenth of the aggregate principal amount of Securities to be purchased on such date, the other Initial Purchasers shall be obligated severally in the
proportions that the principal amount of Firm Securities set forth opposite their respective names in Schedule I bears to the aggregate principal amount of Firm Securities set forth opposite the names of all such
non-defaulting Initial Purchasers, or in such other proportions as the Representatives may specify, to purchase the Securities which such defaulting Initial Purchaser or Initial Purchasers agreed but failed or
refused to purchase on such date; provided that in no event shall the principal amount of Securities that any Initial Purchaser has agreed to purchase pursuant to this Agreement be increased pursuant to this Section 10 by an amount in
excess of one-ninth of such principal amount of Securities without the written consent of such Initial Purchaser. If, on the Closing Date any Initial Purchaser or Initial Purchasers shall fail or refuse to
purchase Firm Securities which it or they have agreed to purchase hereunder on such date and the aggregate principal amount of Securities with respect to which such default occurs is more than one-tenth of the
aggregate principal amount of Firm Securities to be purchased on such date, and arrangements satisfactory to the Representatives and the Company for the purchase of such Firm Securities are not made within 36 hours after such default, this Agreement
shall terminate without liability on the part of any non-defaulting Initial Purchaser or of the Company. In any such case either the Representatives or the Company shall have the right to postpone the Closing
Date, but in no event for longer than seven days, in order that the required changes, if any, in the Time of Sale Memorandum, the Final Memorandum or in any other documents or arrangements may be effected. If, on an Option Closing Date, any Initial
Purchaser or Initial Purchasers shall fail or refuse to purchase Additional Securities and the aggregate principal amount of Additional Securities with respect to which such default occurs is more than
one-tenth of the aggregate principal amount of Additional Securities to be purchased on such Option Closing Date, the non-defaulting Initial Purchasers shall have the
option to (a) terminate their obligation hereunder to purchase the Additional Securities to be sold on such Option Closing Date or (b) purchase not less than the principal amount of Additional Securities that such non-defaulting Initial Purchasers would have been obligated to purchase in the absence of such default. Any action taken under this paragraph shall not relieve any defaulting Initial Purchaser from liability in
respect of any default of such Initial Purchaser under this Agreement. 
 If this Agreement shall be terminated by the Initial Purchasers,
or any of them, because of any failure or refusal on the part of the Company to comply with the terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform its obligations under this
Agreement, the Company will reimburse the Initial Purchasers or such Initial Purchasers as have so terminated this Agreement with respect to themselves, severally, for all
out-of-pocket expenses (including the fees and disbursements of their counsel) reasonably incurred by such Initial Purchasers in connection with this Agreement or the
offering contemplated hereunder. 

  
 31 













 11. Entire Agreement. This Agreement, together with any contemporaneous written
agreements and any prior written agreements (to the extent not superseded by this Agreement) that relate to the offering of the Securities, represents the entire agreement between the Company and the Initial Purchasers with respect to the
preparation of the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum, the conduct of the offering, and the purchase and sale of the Securities. 

(a) The Company acknowledges that in connection with the offering of the Securities: the Initial Purchasers have acted at arms
length, are not agents of, and owe no fiduciary duties to, the Company or any other person, the Initial Purchasers owe the Company only those duties and obligations set forth in this Agreement, any contemporaneous written agreements and prior
written agreements (to the extent not superseded by this Agreement) if any, and the Initial Purchasers may have interests that differ from those of the Company. The Company waives to the full extent permitted by applicable law any claims it may have
against the Initial Purchasers arising from an alleged breach of fiduciary duty in connection with the offering of the Securities. 
 12.
Compliance with USA PATRIOT Act. In accordance with the requirements of the USA PATRIOT Act, the Initial Purchasers are required to obtain, verify and record information that identifies their respective clients, including the Company, which
information may include the name and address of their respective clients, as well as other information that will allow the Initial Purchasers to properly identify their respective clients. 

13. Recognition of the U.S. Special Resolution Regimes. In the event that any Initial Purchaser that is a Covered Entity becomes
subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Initial Purchaser of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be
effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. 

(a) In the event that any Initial Purchaser that is a Covered Entity or a BHC Act Affiliate of such Initial Purchaser becomes
subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Initial Purchaser are permitted to be exercised to no greater extent than such Default Rights could be exercised
under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. 

For purposes of this Section a “BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall
be interpreted in accordance with, 12 U.S.C. § 1841(k). “Covered Entity” means any of the following: (i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. §
252.82(b); (ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12


  
 32 













 
C.F.R. § 382.2(b). “Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as
applicable. “U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act
and the regulations promulgated thereunder. 
 14. Counterparts. This Agreement may be signed in two or more counterparts, each of
which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature complying with the U.S. federal
ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law, e.g., www. Docusign.com) or other transmission method any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for
all purposes. 
 15. Applicable Law. This Agreement and any claim, controversy or dispute relating to or arising out of this
Agreement shall be governed by and construed in accordance with the internal laws of the State of New York. 
 16. Headings. The
headings of the sections of this Agreement have been inserted for convenience of reference only and shall not be deemed a part of this Agreement. 

17. Notices. All communications hereunder shall be in writing and effective only upon receipt and if to the Initial Purchasers shall be
delivered, mailed or sent to the Representatives in care of Morgan Stanley & Co. LLC, 1585 Broadway, New York, New York 10036, Attention: Convertible Debt Syndicate Desk, with a copy to the Legal Department; Goldman
Sachs & Co. LLC, 200 West Street, New York, New York 10282, Attention: Registration Department and J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179, Fax: (212) 622-8358,
Attention: Equity Syndicate Desk; and if to the Company shall be delivered, mailed or sent to Livongo Health, Inc., 150 W. Evelyn Ave, Suite 150, Mountain View, California 94041, Attention: Erica
Palsis.  
 [Signature Page Follows] 

  
 33 













 
			
	Very truly yours,
	
	LIVONGO HEALTH, INC.
		
	 By:
	 	/s/ Lee Shapiro
		 	 Name: Lee Shapiro

		 	 Title: Chief Financial Officer



 Accepted as of the date hereof 

Morgan Stanley & Co. LLC 
 Goldman Sachs & Co.
LLC 
 J.P. Morgan Securities LLC 
 Acting severally on behalf
of themselves and the 
 several Initial Purchasers named 

in Schedule I hereto. 
  

			
	Morgan Stanley & Co. LLC
		
	 By:
	 	/s/ Usman Khan
		 	 Name: Usman Khan

		 	 Title: Managing Director


  

			
	Goldman Sachs & Co. LLC
		
	 By:
	 	/s/ Josh Murray
		 	 Name: Josh Murray

		 	 Title: Managing Director


  

			
	J.P. Morgan Securities LLC
		
	 By:
	 	/s/ David Peoples
		 	 Name: David Peoples

		 	 Title: Managing Director


  
 [Signature Page to Purchase
Agreement] 












 SCHEDULE I 

 

					
	 Initial Purchaser
	  	Principal Amount of
Firm Securities to be
Purchased	 
		
	 Morgan Stanley & Co. LLC
	  	$	196,580,000	 
		
	 Goldman Sachs & Co. LLC
	  	$	108,120,000	 
		
	 J.P. Morgan Securities LLC
	  	$	108,120,000	 
		
	 Piper Sandler & Co.
	  	$	15,545,000	 
		
	 Canaccord Genuity LLC
	  	$	9,327,000	 
		
	 KeyBanc Capital Markets Inc.
	  	$	9,327,000	 
		
	 Needham & Company, LLC
	  	$	9,327,000	 
		
	 Stifel, Nicolaus & Company, Incorporated
	  	$	9,327,000	 
		
	 SVB Leerink LLC
	  	$	9,327,000	 
		  	  
	  
	 
		
	 Total:
	  	$	475,000,000	 
		  	  
	  
	 


  
 I-1 













 SCHEDULE II 

Permitted Communications 
 Time of Sale
Memorandum 
 1. Preliminary Memorandum issued June 1, 2020 

2. Pricing term sheet dated June 1, 2020, attached hereto as Exhibit B 

Permitted Additional Written Offering Communications 
 1.
Investor presentation dated June 2020 
 2. Pricing term sheet dated June 1, 2020, attached hereto as Exhibit B 

Permitted General Solicitations other than Permitted Additional Written Offering Communications set forth above 

None 

  
 II-1 













 EXHIBIT A 

FORM OF LOCK-UP AGREEMENT 

                       
         , 2020 
 Morgan Stanley & Co. LLC 

Goldman Sachs & Co. LLC 
 J.P. Morgan Securities LLC 

 

	c/o	 Morgan Stanley & Co. LLC 



1585 Broadway 
 New York, NY 10036

  

	c/o	 Goldman Sachs & Co. LLC 



200 West Street 
 New York, NY
10282 
  

	c/o	 J.P. Morgan Securities LLC 



383 Madison Avenue 
 New York, NY
10179 
 Ladies and Gentlemen: 
 The
undersigned understands that Morgan Stanley & Co. LLC (“Morgan Stanley”), Goldman Sachs & Co. LLC (“Goldman”) and J.P. Morgan Securities LLC (“J.P. Morgan”) propose to enter into a
Purchase Agreement (the “Purchase Agreement”) with Livongo Health, Inc., a Delaware corporation (the “Company”), providing for the offering (the “Offering”) by the several Initial Purchasers,
including Morgan Stanley, Goldman and J.P. Morgan (the “Initial Purchasers”), of Convertible Senior Notes of the Company (the “Securities”). As used herein, the term “Common Stock” refers to shares
of the Company’s common stock, par value $0.001 per share. 
 To induce the Initial Purchasers that may participate in the Offering to
continue their efforts in connection with the Offering, the undersigned hereby agrees that, without the prior written consent of Morgan Stanley, Goldman and J.P. Morgan, on behalf of the Initial Purchasers, it will not, and will not publicly
disclose an intention to, during the period commencing on the date hereof and ending 60 days after the date of the final offering memorandum (the “Restricted Period”) relating to the Offering (the “Final
Memorandum”), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer, hedge, or dispose
of, directly or indirectly, any shares of Common Stock beneficially owned (as such term is used in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), by the
undersigned 

  
 II-1 













 
or any other securities so owned convertible into or exercisable or exchangeable for Common Stock or (2) enter into any swap, hedging or other arrangement that transfers to another, in whole
or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise,
other than Securities sold pursuant to the Purchase Agreement, if any, or as otherwise provided herein. The undersigned acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transactions designed
or intended, or which could reasonably be expected to lead to or result in, a sale or disposition of any shares of Common Stock, or securities convertible into or exercisable or exchangeable for Common Stock, even if any such sale or disposition
transaction or transactions would be made or executed by or on behalf of someone other than the undersigned. The foregoing sentences in this paragraph shall not apply to (a): 
  

	 	(i)	 transactions relating to shares of Common Stock or other securities acquired in open market transactions after
the completion of the Offering, 


  

	 	(ii)	 transfers of shares of Common Stock or any security convertible into Common Stock as a bona fide gift,
provided that the donees thereof agree to be bound in writing by the restrictions set forth herein, 


  

	 	(iii)	 if the undersigned is a corporation, partnership, limited liability company or other business entity
(A) distributions of shares of Common Stock or any security convertible into shares of Common Stock to partners or stockholders of the undersigned, members, beneficiaries or other equity holders, or (B) to another corporation, partnership,
limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned, or to any investment fund or other entity controlled or managed by
the undersigned, provided that the transferees thereof agree to be bound in writing by the restrictions set forth herein, 


  

	 	(iv)	 (A) to any member of the undersigned’s immediate family or to any trust for the direct or indirect benefit
of the undersigned or the immediate family of the undersigned, or if the undersigned is a trust, to any beneficiary (including such beneficiary’s estate) of the undersigned, provided that the transferee, trustee of the trust, or such
beneficiary agrees to be bound in writing by the restrictions set forth herein, or (B) in any transaction not involving a change in beneficial ownership, provided that the transferee agrees to be bound in writing by the restrictions set
forth herein, 


  

	 	(v)	 by will or intestate succession upon the death of the undersigned, provided that the transferee agrees
to be bound in writing by the restrictions set forth herein, 


  

	 	(vi)	 to the Company in connection with the “net” or “cashless” exercise or settlement of
warrants or stock options or other equity awards pursuant to an employee benefit plan disclosed in the Final Memorandum or in any document 



  
 II-2 














	 	
(or exhibit thereto) incorporated by reference into the Final Memorandum, provided that any such shares of Common Stock received upon such vesting or exercise shall be subject to the terms
of this letter; and provided further that no filing under Section 16(a) of the Exchange Act or other public filing, report or announcement shall be voluntarily made during the Restricted Period and any required filing under
Section 16(a) of the Exchange Act shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this paragraph, 

  

	 	(vii)	 to the Company pursuant to any contractual arrangement that provides the Company with an option to repurchase
such shares of Common Stock in the event the undersigned ceases to provide services to the Company, provided that such contractual arrangement is disclosed in the Final Memorandum or in any document (or exhibit thereto) incorporated by
reference into the Final Memorandum, and provided further that no filing under Section 16(a) of the Exchange Act or other public filing, report or announcement shall be voluntarily made during the Restricted Period and any required
filing under Section 16(a) of the Exchange Act shall clearly indicate in the footnotes thereto that the filing relates to the termination of the undersigned’s employment or other services, 



 

	 	(viii)	 pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction after the
completion of the Offering that is approved by the Board of Directors of the Company and made to all holders of the Company’s capital stock involving a Change of Control (as defined below) of the Company, provided that in the event that
such tender offer, merger, consolidation or other such transaction is not completed, the undersigned’s shares of Common Stock shall remain subject to the provisions of this letter, 



 

	 	(ix)	 by operation of law, such as pursuant to a qualified domestic order or in connection with a divorce settlement,
provided that the transferee agrees to be bound in writing by the restrictions set forth herein, 


  

	 	(x)	 with the prior written consent of Morgan Stanley, Goldman and J.P. Morgan, on behalf of the Initial Purchasers,
or 


  

	 	(xi)	 the transfer of shares of Common Stock pursuant to a written plan meeting the requirements of Rule 10b5-1 under the Exchange Act for the transfer of shares of Common Stock (each, a “10b5-1 Plan”) in effect as of the date hereof which has been provided to
the Initial Purchasers or their legal counsel, provided that any filing required under Section 16(a) of the Exchange Act during the Restricted Period shall clearly indicate in the footnotes thereto that the filing relates to a transaction
pursuant to a 10b5-1 Plan; 


 provided that (x) in the case of any
transfer or distribution pursuant to clauses (a)(ii) through (a)(v), no filing under Section 16(a) of the Exchange Act or other public announcement, reporting a reduction in beneficial ownership of shares of Common


  
 II-3 













 
Stock, shall be required or shall be voluntarily made during the Restricted Period, (y) in the case of any transfer or distribution pursuant to clauses (a)(viii) and (a)(ix), any required
filing or other public announcement under Section 16(a) of the Exchange Act or otherwise, reporting a reduction in beneficial ownership of shares of Common Stock, shall clearly indicate in the footnotes thereto the nature and conditions of such
transfer and no other public announcement shall be made voluntarily during the Restricted Period in connection with such transfer or disposition and (z) in the case of any transfer or distribution pursuant to clauses (a)(ii), (a)(iii), (a)(iv)
and (a)(v), such transfer or disposition shall not involve a disposition for value; or 
 (b) receive from the Company shares
of Common Stock in connection with the exercise of options or the vesting and settlement of restricted stock units or other rights granted under a stock incentive plan or other equity award plan, which plan is described in the Final Memorandum,
provided that any shares issued upon exercise of such option or the vesting and settlement of restricted stock units shall continue to be subject to the restrictions set forth herein until the expiration of this letter and provided
further that that no filing under Section 16(a) of the Exchange Act or other public filing, report or announcement shall be voluntarily made during the Restricted Period and any required filing under Section 16(a) of the Exchange Act
shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this paragraph; or 

(c) the establishment of a Rule 10b5-1 Plan, provided that (i) such plan
does not provide for the transfer of Common Stock during the Restricted Period and (ii) to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the undersigned or the
Company regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of Common Stock may be made under such plan during the Restricted Period. 

In addition, the undersigned agrees that, without the prior written consent of Morgan Stanley, Goldman and J.P. Morgan on behalf of the
Initial Purchasers, it will not, and will not publicly disclose an intention to, during the Restricted Period, make any demand for or exercise any right with respect to, the registration of any shares of Common Stock or any security convertible into
or exercisable or exchangeable for Common Stock. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the undersigned’s shares of Common
Stock except in compliance with the foregoing restrictions. 
 The undersigned acknowledges and agrees that the foregoing precludes the
undersigned from engaging in any hedging or other transactions designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition of any shares of Common Stock, or securities convertible into or exercisable or
exchangeable for Common Stock, even if any such sale or disposition transaction or transactions would be made or executed by or on behalf of someone other than the undersigned. 

  
 II-4 













 For purposes of this letter, “immediate family” shall mean any relationship
by blood, marriage or adoption, not more remote than first cousin. For purposes of this letter, “Change of Control” shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one
transaction or a series of related transactions, to a person or group of affiliated persons (other than an Initial Purchaser pursuant to the Offering), of the Company’s voting securities if, after such transfer, such person or group of
affiliated persons would hold more than 60% of the outstanding voting securities of the Company (or the surviving entity). 
 The
undersigned understands that the Company and the Initial Purchasers are relying upon this agreement in proceeding toward consummation of the Offering. The undersigned further understands that this agreement is irrevocable and shall be binding upon
the undersigned’s heirs, legal representatives, successors and assigns. 
 Whether or not the Offering actually occurs depends on a
number of factors, including market conditions. Any Offering will only be made pursuant to the Purchase Agreement, the terms of which are subject to negotiation between the Company and the Initial Purchasers.     

This agreement and any claim, controversy or dispute arising under or related to this agreement shall be governed by and construed in
accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof. 
 Notwithstanding anything to
the contrary contained herein, this letter will automatically terminate and the undersigned will be released from all obligations hereunder upon the earliest to occur, if any, of (i) the Company advises in writing that it has determined not to
proceed with the Offering prior to the execution of the Purchase Agreement, (ii) the date the Purchase Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of
the Securities to be sold thereunder, or (iii) July 31, 2020, if the Purchase Agreement has not been executed by such date. 

[Signature page follows] 

  
 II-5 













 
			
	 Very truly yours,

	
	 
	 Name of Securityholder (Print exact name)

		
	 By:
	 	 
		 	Signature
	
	 If not signing in an individual capacity:

	
	 
	 Name of Authorized Signatory (Print)

	
	 
	 Title of Authorized Signatory (Print)

	
	 (indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)




  
 A-1 













 EXHIBIT B 

PRICING TERM SHEET